EUCALIA Inc
EUCALIA Inc is a biotechnology company that provides healthcare services and equipment, primarily generating revenue through its operations in the healthcare facilities and services sector.
Business. EUCALIA Inc (286A.T) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
EUCALIA Inc (286A.T) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm is headquartered in Japan and is listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
EUCALIA Inc has a market price of 685.0 JPY and a market capitalization of 24,474,296,500 JPY, with a price-to-earnings ratio of 8.81 and a price-to-book ratio of 1.19. The company's liquidity position is characterized by a current ratio of 2.17, indicating a moderate ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
In terms of profitability, EUCALIA Inc reports a return on equity of 13.53% and a return on assets of 4.26%, which are key indicators of the company's efficiency in generating returns from its equity and total assets. The company's operating income of 2,485,836,000 JPY and net income of 2,776,463,000 JPY reflect its ability to generate profits from its operations.
EUCALIA Inc's revenue is concentrated in the healthcare facilities and services sector, with no disclosed geographic diversification in the provided data. The company's capital expenditure of -920,926,000 JPY indicates a reduction in capital spending, which may affect future growth.
The company's growth trajectory is reflected in its revenue of 24,734,767,000 JPY and gross profit of 10,537,256,000 JPY. Analysts have provided a mean price target of 1,335.00 JPY, with a median price target of 1,335.00 JPY, suggesting a positive outlook on the company's future performance.
EUCALIA Inc faces a medium liquidity risk and a low dilution risk, with a debt-to-equity ratio of 1.43. The company's free cash flow of 3,127,447,000 JPY and operating cash flow of -1,633,902,000 JPY indicate a mixed cash flow position. The company's risk assessment highlights the need for careful monitoring of its liquidity position.
Recent events and filings have not been disclosed in the provided data, but the company's financial performance and analyst estimates suggest a stable outlook.
- EUCALIA Inc has a moderate liquidity position with a current ratio of 2.17.
- The company's return on equity of 13.53% indicates strong profitability relative to its equity base.
- Analysts have a positive outlook on EUCALIA Inc, with a mean price target of 1,335.00 JPY.
- The company's debt-to-equity ratio of 1.43 suggests a balanced capital structure.
- EUCALIA Inc's free cash flow of 3,127,447,000 JPY supports its operational flexibility.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 46,74 |
| Revenue | —no estimate | —no estimate | 30,3B JPY |
| Operating income | —no estimate | —no estimate | 0 JPY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- EUCALIA Inc Market data — financials · 2026-05-26
- EUCALIA Inc Market data — analyst estimates · 2026-05-26